![Three generations of women, grandmother playing with baby in mother’s arms overlayed with blue/orange gradient](https://marengotx.com/wp-content/uploads/2023/12/pipeline-hero.png)
![Three generations of women, grandmother playing with baby in mother’s arms overlayed with blue/orange gradient](https://marengotx.com/wp-content/uploads/2023/12/pipeline-hero-mobile.png)
Powered for progress
and breakthrough.
Partnered with
![Innovations for patient care logo](/wp-content/themes/marengo/dist/images/ipsen-master-logo.png)
Partnered with
![Innovations for patient care logo](/wp-content/themes/marengo/dist/images/ipsen-master-logo.png)
Partnered with
![Innovations for patient care logo](/wp-content/themes/marengo/dist/images/ipsen-master-logo.png)
Tissue agnostic Antigen Rich Tumors in PD1 Resistant Population
Additional solid tumors
Cold tumors
Cold tumors
STAR0602 is Marengo’s first T cell activator generated from Marengo’s STAR platform that provides a ‘dual boost’ to elevate T cells function and response to tumors. STAR0602 acts on a broad range of tumor antigen-specific Vβ6/10 T cells which are prevalent across many common cancer types (approx. 10-12% of TILs in each common cancer). By combining a novel non-clonal mode of TCR activation with a T cell co-stimulator delivered to the same T cells, it promotes the expansion of a new population of clonally diverse, effector memory Vβ 6/10 T cells that turbo-charges the anti-tumor immune response and promotes durable clearance of cancer cells. STAR0602 has undergone extensive preclinical testing, which demonstrates potent anti-tumor activity in both mouse and human ex vivo tumor models attributed to a distinct mechanism of action from existing cancer immunotherapies.
![Scientific illustration of START0602 mechanism of action](https://marengotx.com/wp-content/uploads/2023/12/scientific-illustration-of-START0602.png)
![Scientific illustration of START0602 mechanism of action](https://marengotx.com/wp-content/uploads/2023/12/scientific-illustration-mobile.png)
![Marengo START001 logo](https://marengotx.com/wp-content/uploads/2023/12/marengo-start-001-logo.png)
START-001 is a Phase I/II clinical trial evaluating the safety, tolerability, and preliminary clinical activity of STAR0602 as a single agent in biomarker selected patients with advanced antigen-rich solid tumors including PD-1 refractory and rare tumors. This open-label, multi-center trial consists of two parts: Phase I dose escalation and Phase II dose expansion. For more information, please visit clinicaltrials.gov (trial identifier: NCT05592626).
For patients interested in enrolling in this study contact: kliu@marengotx.com
![National Institutes of Health logo](https://marengotx.com/wp-content/uploads/2023/12/nih-logo.png)
![Massachusetts General Hospital Cancer Center logo](https://marengotx.com/wp-content/uploads/2023/12/mgh-logo.png)
![Memorial Sloan Kettering Cancer Center logo](https://marengotx.com/wp-content/uploads/2023/12/mskcc-logo.png)
![The Princess Margaret Cancer Foundation logo](https://marengotx.com/wp-content/uploads/2023/12/pmcf-logo.png)
![AdventHealth logo](https://marengotx.com/wp-content/uploads/2023/12/ah-logo.png)
![3D illustration of T cells attacking cancer cells overlayed with blue background.](https://marengotx.com/wp-content/uploads/2022/04/pipeline-page-last-section.jpg)